Discontinuation of nucleos(t)ide analogues after NA-induced HBsAg seroclearance: a single-center 48-week retrospective study
In this single-center cohort, most non-cirrhotic patients who achieved HBsAg seroclearance on long-term NAs therapy maintained HBsAg loss over 48 weeks after discontinuation. HBcrAg positivity at end of treatment was observed in all cases of HBsAg reappearance, suggesting HBcrAg may help identify patients at higher short-term risk of seroreversion. Larger, longer-term studies are required to confirm these findings.
Authors
- En‐Qiang Chen (ORCID: https://orcid.org/0000-0002-8523-1689)
- Jiangnan Peng (ORCID: https://orcid.org/0000-0001-5785-737X)
- Meng-Lan Wang (ORCID: https://orcid.org/0009-0006-5525-3189)
- Yong‐Hong Wang (ORCID: https://orcid.org/0000-0002-3415-8397)
- Ya-Chao Tao
- Cheng-Run Song (ORCID: https://orcid.org/0000-0002-8142-4600)
Institutions
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
Publication Details
- Journal
- Journal of Virus Eradication
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1016/j.jve.2025.100617
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00